Standard care plus compounds studied in the literature, organized by clinical readiness.
Standard care plus every compound studied in the literature (each cited) and graded by evidence, organized by clinical readiness. A category, not a verdict that anything works — confirm anything here with your oncology team.
Tested in people, by trial phase: Phase III ×4 · Phase II ×10 · Phase I ×4 · phase not reported ×5
Columns group into clinical evidence (used in, or tested on, people) and preclinical evidence (lab/animal, or only named in the literature). Cell = number of interventions; a dashed cell means none recorded there.
| bevacizumab FDA-approved for this cancer. | — | Guideline option | |
| olaparib FDA-approved for this cancer. | — | Guideline option | |
| rucaparib FDA-approved for this cancer. | — | Guideline option | |
| Mirvetuximab Soravtansine FDA-approved for this cancer. | — | Guideline option |
| pembrolizumab FDA-approved for this cancer. | — | Guideline option |
| relacorilant FDA-approved for this cancer. | — | Guideline option |
"Tested in people" rows show the highest trial phase found in that compound's cited human studies (Phase I–IV; "phase not reported" = a human study with no phase tag). "Studied" = named in the cited literature for this cancer. "FDA ✓" = FDA-approved for this cancer; "off-label" = an FDA-approved drug used outside its approved indications (per openFDA). Not a claim that anything works.